LLY Eli Lilly and Company Loading...

From CI earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:30
Jul 30 ◎
Brian Evanko CI Q2 FY26 call
Moderating GLP-1 growth rates with slight decline in coverage levels; Cigna omitted GLP-1 weight loss drugs from its own employee plan citing affordability. — Signals potential top-line pressure for GLP-1 manufacturers if large employers follow suit; however, this is offset by the specialty business outperformance.
LLY
MED

About LLY Analyst Coverage

Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Brian Evanko.